A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis-Reference-Cited by-同舟云学术

A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis

Published:2024-07-25 Issue:4 Volume:391 Page:311-319
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Sanyal Arun J.¹,Bedossa Pierre¹,Fraessdorf Mandy¹,Neff Guy W.¹,Lawitz Eric¹,Bugianesi Elisabetta¹,Anstee Quentin M.¹,Hussain Samina Ajaz¹,Newsome Philip N.¹^ORCID,Ratziu Vlad¹,Hosseini-Tabatabaei Azadeh¹,Schattenberg Jörn M.¹^ORCID,Noureddin Mazen¹,Alkhouri Naim¹^ORCID,Younes Ramy¹

Affiliation:

1. From the Stravitz–Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University School of Medicine, Richmond (A.J.S.); Liverpat and University of Paris (P.B.), and Sorbonne Université, Institute for Cardiometabolism and Nutrition, Assistance Publique–Hôpitaux de Paris, INSERM Unité Mixte de Recherche Scientifique 1138, Centre de Recherche des Cordeliers (V.R.) — all in Paris; Boehringer Ingelheim, Ingelheim am Rhein (M.F., S.A.H and R.Y.), Saarland University Medical...

Funder

Boehringer Ingelheim

Publisher

Massachusetts Medical Society

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2401755

Reference30 articles.

1. A multisociety Delphi consensus statement on new fatty liver disease nomenclature

2. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review

3. Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons

4. Changing epidemiology, global trends and implications for outcomes of NAFLD

5. FDA approves first treatment for patients with liver scarring due to fatty liver disease. Food and Drug Administration March 14 2024 (https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease).

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diabetes as a risk factor for MASH progression;Diabetes Research and Clinical Practice;2024-11

2. Natural history and progression of metabolic dysfunction-associated steatotic liver disease;The Lancet Gastroenterology & Hepatology;2024-10

3. GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction;Nature Reviews Gastroenterology & Hepatology;2024-09-06

4. Dietary protein defends lean mass and maintains the metabolic benefits of glucagon receptor agonism in mice;Molecular Metabolism;2024-09

5. Paradigm shift in steatotic liver disease (SLD): from NAFLD to MASLD;Kanzo;2024-09-01